CANCER SURVIVORSHIP AND EXERCISE ONCOLOGY
Professor Sandra Hayes, Director of Research
Cancer Council Queensland (CCQ), Brisbane, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Australia | April 2025
Professor Sandra Hayes is the Director of Research at Cancer Council Queensland (CCQ), where she leads a comprehensive cancer research program encompassing cancer epidemiology, prevention, detection, treatment, and survivorship.
With a BAppSci (Hons) and a PhD in exercise oncology, Professor Hayes’s expertise lies in quantifying the impact of cancer diagnosis and treatment on physical and psychosocial wellbeing, quality of life, and survival. She also evaluates innovative supportive care strategies, particularly exercise, to improve post-cancer lives.
Professor Hayes has authored 170 peer-reviewed publications, been a Chief Investigator on grants totalling more than AUD$20M, leading world-renowned randomised trials and longitudinal oncology cohort studies involving over 9000 participants across more than 10 cancer sites. Recognised internationally as an expert in exercise oncology, Professor Hayes has held executive positions on national and international committees, including the Clinical Oncology Society of Australia and the International Society of Lymphology.
Her research has been funded by several organisations over the past 25 years, including government funding support through National Health and Medical Research Council grants and more recently the Medical Research Future Fund. Professor Hayes has also been supported from funding from organisations such as the National Breast Cancer Foundation and Cancer Council Queensland, as well as international funding from the World Cancer Research Fund.
Her professional activities include peer review for top oncology and exercise science journals and advisory roles for various cancer and exercise organisations. Her research impact includes leading national and international position statements on exercise for cancer patients, co-developing the Clinical Oncology Society of Australia’s physical activity guidelines, and creating resources for the International Exercise is Medicine® campaign.
She has also developed the YWCA Encore breast cancer rehabilitation program and lymphoedema diagnostic criteria used globally.
Source: Supplied
https://orcid.org/0000-0002-7005-5184
-
New treatments for patients with mental illness
Associate Professor Bernadette Fitzgibbon is a neuroscientist with several decades of experience in researching, developing, and translating novel therapies for mental health and chronic pain conditions. This includes the application and optimisation of brain stimulation and psychedelic therapies, overseeing large multi-site intervention trials, both within Australia and abroad. Through her work, she has developed meaningful collaborations with consumers, volunteers, policy makers, and services providers, ensuring that the outcomes of her work contribute towards real-world clinical impact.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
At the frontier of human cellular neuroscience research
Associate Professor Cedric Bardy is the Director of The Laboratory for Human Neurophysiology, Genetics & Stem Cells, located at SAHMRI. South Australia.
His current research uses preclinical, patient-derived cell models to test innovative therapeutic strategies, with a current focus on Parkinson’s disease, brain cancer and childhood dementia (Sanfilippo syndrome).
His work has established a platform to facilitate the discovery and validation of treatments for brain disorders. Their research is at the frontier of human cellular neuroscience research and translational applications that benefit global public health.
